JPRN-UMIN000023627已完成未知
The efficacy and safety of enzalutamide for castrate-resistant prostate cancer patient showing disease progression after or during chemotherapy including docetaxel. - The efficacy and safety of enzalutamide on castrate-resistant prostate cancer after docetaxel treatment.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1) contraindication for enzalutamide 2) history of seizure (including febrile seizure), loss of consciousness. 3) symptom of temporal brain ischemia or warning sign of seizure within a year 4) judged as inappropriate by the investigator.
研究者
相似试验
尚未招募
2 期
The efficacy and safety of enzalutamide in patients with non-muscle invasive bladder cancernon-muscle invasive bladder cancerJPRN-UMIN000026520rology department of Tsukuba University Hospital10
已完成
不适用
Investigation of clinical efficacy of Enzalutamide and its predictive factors in CRPC patientscastration resistant prostate cancerJPRN-UMIN000015996Keio University School of Medicine50
已完成
2 期
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast CancerAdvanced, Androgen Receptor Positive Triple Negative Breast CancerNCT01889238Pfizer118
进行中（未招募）
1 期
Research study that is testing a new treatment combination for localised prostate cancer that is going to be treated with radiotherapy. This study is looking at combining a new drug, enzalutamide, with the current best available treatments in order to improve outcomes for men in this situation. This is a randomised controlled trial which means that half the participants on the trial will get enzalutamide and the other half will get current standard of care.EUCTR2014-003191-23-IECancer Trials Ireland800
进行中（未招募）
1 期
Research study that is testing a new treatment combination for localised prostate cancer that is going to be treated with radiotherapy. This study is looking at combining a new drug, enzalutamide, with the current best available treatments in order to improve outcomes for men in this situation. This is a randomised controlled trial which means that half the participants on the trial will get enzalutamide and the other half will get current standard of care.ocalised prostate cancer at high risk of recurrenceMedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003191-23-SICancer Trials Ireland800